These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950 [TBL] [Abstract][Full Text] [Related]
6. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies. Kim SY; Song IC; Kim J; Kwon GC Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470 [TBL] [Abstract][Full Text] [Related]
7. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Szuber N; Orazi A; Tefferi A Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693 [TBL] [Abstract][Full Text] [Related]
13. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML. Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367 [TBL] [Abstract][Full Text] [Related]
14. A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications. Mitsumori T; Komatsu N; Kirito K Intern Med; 2016; 55(4):405-7. PubMed ID: 26875968 [TBL] [Abstract][Full Text] [Related]
15. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation. Ikeda Y; Yamanouchi J; Takenaka K Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732 [No Abstract] [Full Text] [Related]
16. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229 [TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714 [No Abstract] [Full Text] [Related]
18. What's different about atypical CML and chronic neutrophilic leukemia? Dao KH; Tyner JW Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732 [TBL] [Abstract][Full Text] [Related]
19. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671 [TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia. Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]